The Nemours Foundation

Marshall Z Schwartz

Darlise O'Connor

The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Inflammatory bowel disease as defined by the present invention, includes Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the intestine, immunodeficiency syndromes affecting the intestine, and HIV. Mucosal damage and histologic lesions are reduced by administering an effective dose of HGF to patients suffering from the same. Specifically, the effective dose of HGF is in a range of about 30 &#x3bc;g/kg body weight/day to about 300 &#x3bc;g/kg body weight/day. HGF may be administered to the patient lumenally or systemically.

Treatment of intestinal epithelial cell malfunction, inflammation or damage with Hepatocyte growth factor

A method for treating a patient that has inadequate intestinal function is described. Administering leptin to a subject increases the intestinal function beyond that for a normal intestine and beyond that of a normal adaptive response. Further, administering leptin to a subject results in an increase in amino acid absorption, sugar absorption, mucosal mass, transport mechanisms for amino acids, or transport mechanisms for sugars. The method may be used for treating subjects have conditions such as short bowel syndrome, inflammation of the bowel, necrotizing enterocolitis, intestinal atresia, midgut volvulus, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the small intestine, and inflammatory bowel disease such as, chronic ulcerative colitis and Crohn's Disease.

Intestinal function using leptin

The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Mucosal damage and histologic lesions are reduced by administering HGF to patients suffering from the same. HGF may be administered to the patient lumenally or systemically.

Method and composition for the treatment of inflammatory bowel disease

Reversal of reduced intestinal mucosal mass and absorptive function in patients by the administration of low doses of exogenous HGF either systemically or intraluminally.

Growing community of inventors

Bryn Mawr, PA, United States of America

Marshall Z Schwartz